Sunir Garg, MD

Sunir J. Garg, MD, FACS, FASRS, is professor of ophthalmology at Wills Eye Hospital and Thomas Jefferson University, and partner at Mid Atlantic Retina.

Articles by Sunir Garg, MD

How Insurance, Socioeconomic Barriers Derail DME Care: Sunir J. Garg, MD

ByLaura Joszt, MA,Sunir Garg, MD

June 29th 2026

Insurance and socioeconomic factors delay optimal anti-VEGF care for diabetic macular edema, worsening vision disparities.

Catching DME Patients Before They Fall Off the Radar: Sunir Garg, MD

ByLaura Joszt, MA,Sunir Garg, MD

June 22nd 2026

Hidden costs, travel, and dilation can derail DME care, but clinicians can build adherence plans that keep working adults on vision-saving therapy.

Sunir Garg, MD

Articles by Sunir Garg, MD

How Insurance, Socioeconomic Barriers Derail DME Care: Sunir J. Garg, MD

Catching DME Patients Before They Fall Off the Radar: Sunir Garg, MD

Latest Updated Articles

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

Kerry Rogers, MD, on BTK Inhibitor Selection and Tolerability in CLL

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

An Interview With Lucio Gordan, MD: Community Oncology and CAR T-Cell Therapy

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Sunir Garg, MD

Articles by Sunir Garg, MD

How Insurance, Socioeconomic Barriers Derail DME Care: Sunir J. Garg, MD

Catching DME Patients Before They Fall Off the Radar: Sunir Garg, MD

Latest Updated Articles

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

Kerry Rogers, MD, on BTK Inhibitor Selection and Tolerability in CLL

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

An Interview With Lucio Gordan, MD: Community Oncology and CAR T-Cell Therapy